Kildebibliotek
Alle studier og myndighetskilder vi bruker, samlet på ett sted. Filtrer på studietype og hva som er studert.
Viser 81 av 81 kilder
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
Jastreboff AM, Kaplan LM, Davies MJ, et al. N Engl J Med. 2026.
Brukt i: Retatrutide, Hva er peptider?, Slik leser du en studie, GLP-1, GIP og glukagon forklart, Regelverk i Norge, Rettelser
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
Bajaj HS, Welch M, Shah P, et al. Lancet. 2026.
Brukt i: Retatrutide
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Mendias CL, Awan TM. Sports Med. 2026.
Brukt i: TB-500, Tymosin beta-4, Hva er peptider?
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
Mayfield CK, Bolia IK, Feingold CL, et al. Am J Sports Med. 2026.
Brukt i: TB-500, Tymosin beta-4, GHK-Cu
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Rahman OF, et al. J Am Acad Orthop Surg Glob Res Rev. 2026.
Brukt i: TB-500
Thymosin beta-4, TMSB4X, human (P62328).
UniProt. 2026.
Brukt i: Tymosin beta-4
GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap.
Mateescu DM, et al. Pharmaceutics. 2026.
Brukt i: GHK-Cu
CosIng: Copper Tripeptide-1 (cosmetic ingredient).
European Commission. 2026.
Brukt i: GHK-Cu, Regelverk i Norge
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo (NCT07437560).
ClinicalTrials.gov. 2026.
Brukt i: Melanotan II
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (NCT07505745).
ClinicalTrials.gov. 2026.
Brukt i: MOTS-c
Wegovy (semaglutide): EPAR. Authorised in the EU on 06.01.2022. Prescription only.
European Medicines Agency (EMA). 2026.
Brukt i: Semaglutid, Hva er peptider?, GLP-1, GIP og glukagon forklart, Regelverk i Norge, Antidoping
Mounjaro (tirzepatide): EPAR. Authorised in the EU on 15.09.2022. Prescription only.
European Medicines Agency (EMA). 2026.
Brukt i: Tirzepatid, Hva er peptider?, GLP-1, GIP og glukagon forklart, Regelverk i Norge, Antidoping
BPC 157 (CID 9941957).
PubChem, National Library of Medicine. 2026.
Brukt i: BPC-157
TB-500 (CID 62707662).
PubChem, National Library of Medicine. 2026.
Brukt i: TB-500, Tymosin beta-4
MOTS-c (CID 146675088).
PubChem, National Library of Medicine. 2026.
Brukt i: MOTS-c
Semax (CID 9811102).
PubChem, National Library of Medicine. 2026.
Brukt i: Semax
Lys-Pro-Val (KPV) (CID 125672).
PubChem, National Library of Medicine. 2026.
Brukt i: KPV
Melanotan II (CID 92432).
PubChem, National Library of Medicine. 2026.
Brukt i: Melanotan II
Ipamorelin (CID 9831659).
PubChem, National Library of Medicine. 2026.
Brukt i: CJC-1295 og ipamorelin
Copper tripeptide-1 (GHK-Cu) (CID 71587328).
PubChem, National Library of Medicine. 2026.
Brukt i: GHK-Cu
Import av legemidler til personlig bruk ved forsendelse.
Direktoratet for medisinske produkter (DMP). 2026.
Brukt i: Regelverk i Norge
Legemidler på reise inn til Norge.
Direktoratet for medisinske produkter (DMP). 2026.
Brukt i: Regelverk i Norge
Er produktet et legemiddel?
Direktoratet for medisinske produkter (DMP). 2026.
Brukt i: Regelverk i Norge
The 2026 Prohibited List. International Standard.
World Anti-Doping Agency (WADA). 2026.
Brukt i: Retatrutide, TB-500, Tymosin beta-4, Semaglutid, Tirzepatid, GHK-Cu, Melanotan II, MOTS-c, Semax, KPV, CJC-1295 og ipamorelin, Antidoping
Seks peptider på dopinglisten av hensyn til folkehelsen.
Direktoratet for medisinske produkter (DMP). 2026.
Brukt i: Retatrutide, TB-500, Tymosin beta-4, GHK-Cu, Melanotan II, MOTS-c, Semax, KPV, CJC-1295 og ipamorelin, Regelverk i Norge
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
Vasireddi N, Hahamyan H, Salata MJ, et al. HSS J. 2025.
Brukt i: BPC-157, Slik leser du en studie
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
McGuire FP, Martinez R, Lenz A, et al. Curr Rev Musculoskelet Med. 2025.
Brukt i: BPC-157
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
Lee E, Burgess K. Altern Ther Health Med. 2025.
Brukt i: BPC-157
MOTS-C levels in individuals with and without obesity and its association with inflammation, insulin resistance and endothelial dysfunction.
Ozkaya DY, Haymana C, et al. Arch Endocrinol Metab. 2025.
Brukt i: MOTS-c
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, Horn DB, le Roux CW, et al. N Engl J Med. 2025.
Brukt i: Tirzepatid
Next generation dual GLP-1/GIP, GLP-1/glucagon, and triple GLP-1/GIP/glucagon agonists: a literature review.
Wen J, et al. Nutr Metab Cardiovasc Dis. 2025.
Brukt i: GLP-1, GIP og glukagon forklart
Netthandel: registreringsordning for nettapotek og andre utsalgssteder.
Direktoratet for medisinske produkter (DMP). 2025.
Brukt i: Regelverk i Norge
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Sanyal AJ, Kaplan LM, Frias JP, et al. Nat Med. 2024.
Brukt i: Retatrutide
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
Lee E, Walker C, Ayadi B. Altern Ther Health Med. 2024.
Brukt i: BPC-157
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
Aronne LJ, Sattar N, Horn DB, et al. JAMA. 2024.
Brukt i: Tirzepatid
Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP, et al. N Engl J Med. 2023.
Brukt i: Retatrutide
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J, et al. Lancet. 2023.
Brukt i: Retatrutide
Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction (NCT05984134).
ClinicalTrials.gov. 2023.
Brukt i: TB-500, Tymosin beta-4, Rettelser
MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.
Zheng Y, Wei Z, Wang T. Front Endocrinol (Lausanne). 2023.
Brukt i: MOTS-c
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. N Engl J Med. 2023.
Brukt i: Semaglutid, GLP-1, GIP og glukagon forklart
Doping.
Direktoratet for medisinske produkter (DMP). 2023.
Brukt i: Antidoping
0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial.
Sosne G, Kleinman HK, Springs C, et al. Int J Mol Sci. 2022.
Brukt i: Tymosin beta-4
Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022.
Brukt i: Tirzepatid, GLP-1, GIP og glukagon forklart
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
Lee E, Padgett B. Altern Ther Health Med. 2021.
Brukt i: BPC-157
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
Reynolds JC, Lai RW, Woodhead JST, et al. Nat Commun. 2021.
Brukt i: MOTS-c
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021.
Brukt i: Semaglutid
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021.
Brukt i: Tirzepatid
Trends in peptide drug discovery.
Muttenthaler M, King GF, Adams DJ, Alewood PF. Nat Rev Drug Discov. 2021.
Brukt i: Hva er peptider?, Slik jobber vi
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Kingsberg SA, Clayton AH, Portman D, et al. Obstet Gynecol. 2019.
Brukt i: Melanotan II
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.
Pickart L, Margolina A. Int J Mol Sci. 2018.
Brukt i: GHK-Cu
A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease (NCT03998514).
ClinicalTrials.gov. 2018.
Brukt i: MOTS-c
The efficacy of semax in the treatment of patients at different stages of ischemic stroke. In Russian.
Gusev EI, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2018.
Brukt i: Semax
Effects of Semax on the Default Mode Network of the Brain.
Lebedeva IS, Panikratova YR, Sokolov OY, et al. Bull Exp Biol Med. 2018.
Brukt i: Semax, Slik leser du en studie
Ozempic (semaglutide): EPAR. Authorised in the EU on 08.02.2018.
European Medicines Agency (EMA). 2018.
Brukt i: Semaglutid, GLP-1, GIP og glukagon forklart
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
Drucker DJ. Cell Metab. 2018.
Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.
Xiao B, et al. Mol Ther. 2017.
Brukt i: KPV
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C, Harashima SI, Tsoukas GM, et al. Lancet Diabetes Endocrinol. 2017.
Brukt i: Semaglutid
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016.
Brukt i: Semaglutid
Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
Sosne G, Dunn SP, Kim C. Cornea. 2015.
Brukt i: TB-500, Tymosin beta-4
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.
Sosne G, Ousler GW. Clin Ophthalmol. 2015.
Brukt i: Tymosin beta-4
Afamelanotide for Erythropoietic Protoporphyria.
Langendonk JG, Balwani M, Anderson KE, et al. N Engl J Med. 2015.
Brukt i: Melanotan II
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
Lee C, Zeng J, Drew BG, et al. Cell Metab. 2015.
Brukt i: MOTS-c, Hva er peptider?
Scenesse (afamelanotide): EPAR. Authorised in the EU on 22.12.2014.
European Medicines Agency (EMA). 2014.
Brukt i: Melanotan II
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.
Beck DE, et al. Int J Colorectal Dis. 2014.
Brukt i: CJC-1295 og ipamorelin
Lost in translation: animal models and clinical trials in cancer treatment.
Mak IW, Evaniew N, Ghert M. Am J Transl Res. 2014.
Brukt i: Slik leser du en studie, Slik jobber vi
The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients.
Treadwell T, Kleinman HK, Crockford D, et al. Ann N Y Acad Sci. 2012.
Brukt i: Tymosin beta-4
The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study.
Stavchansky VV, et al. J Mol Neurosci. 2011.
Brukt i: Semax
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function (NCT01280344).
ClinicalTrials.gov. 2011.
Brukt i: CJC-1295 og ipamorelin
The effect of thymosin treatment of venous ulcers.
Guarnera G, DeRosa A, Camerini R. Ann N Y Acad Sci. 2010.
Brukt i: TB-500, Tymosin beta-4
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. Gastroenterology. 2008.
Brukt i: KPV
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.
Kannengiesser K, Maaser C, Heidemann J, et al. Inflamm Bowel Dis. 2008.
Brukt i: KPV, Hva er peptider?
Biology of incretins: GLP-1 and GIP.
Baggio LL, Drucker DJ. Gastroenterology. 2007.
Brukt i: GLP-1, GIP og glukagon forklart
Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.
Dolotov OV, et al. J Neurochem. 2006.
Brukt i: Semax
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Teichman SL, et al. J Clin Endocrinol Metab. 2006.
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006.
Brukt i: CJC-1295 og ipamorelin
alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.
Elliott RJ, et al. J Invest Dermatol. 2004.
Brukt i: KPV
Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction.
Wessells H, Gralnek D, Dorr R, et al. Urology. 2000.
Brukt i: Melanotan II
Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study.
Wessells H, Fuciarelli K, Hansen J, et al. J Urol. 1998.
Brukt i: Melanotan II
Ipamorelin, the first selective growth hormone secretagogue.
Raun K, Hansen BS, Johansen NL, et al. Eur J Endocrinol. 1998.
Brukt i: CJC-1295 og ipamorelin
Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). In Russian.
Gusev EI, Skvortsova VI, Miasoedov NF, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 1997.
Brukt i: Semax
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
Dorr RT, Lines R, Levine N, et al. Life Sci. 1996.
Brukt i: Melanotan II
Ingen kilder passer filteret.